Adalvo and EQL Pharma have established a formidable partnership, entering into a strategic licensing agreement for Mellozzan® (with active ingredient melatonin). This collaboration grants Adalvo exclusive rights to register, commercialize, and distribute products across 89 countries, solidifying our global reach and market presence. Among the countries are large markets such as China, Brazil, Canada, Egypt and Japan.
Mellozzan® contains the sleep hormone melatonin and is indicated for children who have ADHD and suffer from insomnia. Melatonin is widely used for insomnia throughout the world, but the ADHD indication of Mellozzan® does not exist for any melatonin medicine outside of Europe. Mellozzan® is also indicated in the short-term treatment of jet lag in adults.